RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)
The ultimate 360° Tracker Your financial life in one place, automatically

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
BUY

Pfizer Inc(PFE)

Aug 09, 2005
It's in a big trading range of $25/29. Don't let it go below the low of $24. Hopefully it will break up through the trend line. You should be in this for at least 2 years.
Photo of Bill CarriganBill CarriganUnlock Rating
$26.70

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 04, 2005
Has a model price of $38.43.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.60

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 20, 2005
They beat the numbers today. Numbers are pretty low. They are taking costs out. The problems with these stocks, which are all innovation dependent, is essentially depletion through generics.
Photo of Danny TomkaDanny Tomka
No
Unlock Rating
$27.06

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 19, 2005
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. This one has been under a bit of a cloud, but it's cheap on an earnings basis.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$27.38

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 13, 2005
Growth rate went from 30% three years ago to almost low single digits or flat. Not performing well. The group is in the early stages of a turn around, but would be more inclined to buy the company that has flourished through this period. Would prefer Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.23

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 06, 2005
The whole area has been beaten up and is very interesting. The big pharmas have a big challenge as the pipelines are a little bit bare. Would rather own companies that are suppliers to the pharmas, such as IMS Health (RX-N). (He doesn't follow big caps.)
Photo of Phil TallerPhil Taller
No
Unlock Rating
$26.77

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 02, 2005
RE:Call options Jan/07. Not particularily expensive as it has not been a volatile stock. Not a bad way to play the stock if you are bullish on the company. The company has a very good dividend, so call option are less than the put options quite often. (His play on this is through the Vipers (VHT-A).)
Photo of Richard CroftRichard Croft
No
Unlock Rating
$27.50

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 25, 2005
Got in on the Celebrex recall. This company has developed some fantastic drugs. Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. 3.5% didvidend yield while you wait for a recovery. Generates a ton of free cash flow. Merck & Company (MRK-N) are in the same way.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$27.03

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 11, 2005
This company, along with the other drug stocks, has had a very big problem. Fell below its 200 day moving average. There is no base.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$26.46

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 28, 2005
(A Top Pick Jan24/05. Up 8%.) Still likes.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.23

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Mar 21, 2005
Pharmaceuticals have pretty good cash flows, but their stocks are going nowhere. Cheap on a relative basis to where they've been. Have one big overhang as a group, i.e., there are a lot of patent expiries that are going to happen in 2006. May not be a bad time to start picking them up.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$25.71

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2005
A good long term hold. Historically cheap.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$26.29

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 25, 2005
Likes the pharmaceutical industry. The market is not thinking about the tremendous amount of cash they throw off and that they are cheap. Made the right move by not taking Celebrex off the market. Good pipeline.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.86

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2005
In their top 10. Great valuation.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 18, 2005
FDA has given the OK on the controversial drugs. Pfizer is a very strong company and has the best pipeline of all the large drug companies. Continues to generate billions of $'s of free cash flow. YOu won't get rich, but you'll make some money.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$26.80

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 661 to 675 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica